Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease 4, Autosomal Dominant Lewy Body

Explore clinical trials studying Parkinson Disease 4, Autosomal Dominant Lewy Body. Study availability and eligibility vary by location and protocol.

226 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Completed

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

NCT04305041

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +10 more
Locations
  • The Angeles Clinic and Research Institute ( Site 1009) Los Angeles, California, United States
  • UCLA Hematology & Oncology ( Site 1004) Los Angeles, California, United States
  • Providence Saint John's Health Center ( Site 1010) Santa Monica, California, United States
  • University of Colorado, Anschutz Cancer Pavilion ( Site 1012) Aurora, Colorado, United States
View all 36 locations
View Trial Details
Completed

Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

NCT03715205

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +18 more
Locations
  • Nizam's Institute of Medical Sciences ( Site 0011) Hyderabad, Andhra Pradesh, India
  • Artemis Health Institute ( Site 0007) Gurgaon, Haryana, India
  • Tata Memorial Hospital [M] ( Site 0005) Mumbai, Maharashtra, India
  • Kokilaben Ben Dhirubhai Ambani Hosp & Med Res Inst. ( Site 0001) Mumbai, Maharashtra, India
View Trial Details
Completed

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

NCT03322540

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Pacific Cancer Medical Center, Inc. Anaheim, California, United States
  • Innovative Clinical Research Institute Whittier, California, United States
  • Florida Cancer Specialists (South Region) Fort Myers, Florida, United States
  • Florida Cancer Specialists (North Region) St. Petersburg, Florida, United States
View all 101 locations
View Trial Details
Completed

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

NCT03361865

Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body, UC (Urothelial Cancer)
Locations
  • Arizona Oncology Associates PC- HOPE Tucson, Arizona, United States
  • University of California Irvine Medical Center Orange, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Woodlands Medical Specialists, PA Pensacola, Florida, United States
View all 143 locations
View Trial Details
Completed

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

NCT03374488

Conditions
Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +4 more
Locations
  • Ironwood Cancer & Research Centers Chandler, Arizona, United States
  • University of California Irvine Medical Center Orange, California, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • UCLA Hematology Oncology Santa Monica Santa Monica, California, United States
View all 135 locations
View Trial Details
Completed

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

NCT03976375

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 1604) Bakersfield, California, United States
  • Cancer Specialists of North Florida - Fleming Island ( Site 1675) Fleming Island, Florida, United States
  • Mid-Florida Cancer Centers ( Site 1611) Orange City, Florida, United States
  • University of Kentucky School of Medicine & Hospitals ( Site 1621) Lexington, Kentucky, United States
View all 143 locations
View Trial Details
Completed

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

NCT04725188

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Cedars-Sinai Medical Center ( Site 2522) Los Angeles, California, United States
  • Illinois Cancer Care ( Site 2534) Peoria, Illinois, United States
  • Baptist Health Lexington-Research ( Site 2502) Lexington, Kentucky, United States
  • University of Maryland ( Site 2528) Baltimore, Maryland, United States
View all 95 locations
View Trial Details
Completed

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

NCT05007106

Conditions
Adenocarcinoma, Adnexal Diseases, Biliary Tract Diseases, +52 more
Locations
  • Alaska Womens Cancer Care ( Site 1016) Anchorage, Alaska, United States
  • City of Hope Comprehensive Cancer Center ( Site 1001) Duarte, California, United States
  • University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente Orange, California, United States
  • Karmanos Cancer Institute ( Site 1007) Detroit, Michigan, United States
View all 73 locations
View Trial Details
Completed

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

NCT02903914

Conditions
Adenocarcinoma, Adenoma, Bladder Cancer, +49 more
Locations
  • University of South Alabama Mobile, Alabama, United States
  • Honor Health/Pinnacle Oncology Hematology Scottsdale, Arizona, United States
  • University of Arizona Tucson, Arizona, United States
  • Georgetown Washington D.C., District of Columbia, United States
View all 20 locations
View Trial Details

Related conditions